$ENTX
Entera Bio Ltd

2024 Q1 Form 10-K Financial Statement

#000117891324000881 Filed on March 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Gross Profit $0.00 $0.00
YoY Change -100.0% -100.0%
Gross Profit Margin
Selling, General & Admin $973.0K $4.430M
YoY Change -44.11% -38.92%
% of Gross Profit
Research & Development $735.0K $1.000M $4.510M
YoY Change -21.05% -25.98% -22.88%
% of Gross Profit
Depreciation & Amortization $13.00K $13.00K $56.00K
YoY Change -7.14% -18.75% -12.5%
% of Gross Profit
Operating Expenses $2.062M $1.963M $8.891M
YoY Change -6.78% -36.14% -31.87%
Operating Profit -$2.062M -$1.963M -$8.891M
YoY Change -6.78% -36.02% -31.7%
Interest Expense -$32.00K $31.00K
YoY Change -62.65%
% of Operating Profit
Other Income/Expense, Net $45.00K $31.00K
YoY Change 104.55% -62.65%
Pretax Income -$1.995M -$8.860M
YoY Change -35.25% -31.5%
Income Tax $0.00 $29.00K
% Of Pretax Income
Net Earnings -$2.017M -$1.995M -$8.889M
YoY Change -7.9% -34.27% -31.99%
Net Earnings / Revenue
Basic Earnings Per Share $0.05 $0.31
Diluted Earnings Per Share $0.05 -$0.07 -$0.31
COMMON SHARES
Basic Shares Outstanding 35.48M shares 28.81M shares 29.01M shares
Diluted Shares Outstanding 36.74M shares 29.01M shares

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.189M $11.02M $11.02M
YoY Change -14.05% -10.48% -10.48%
Cash & Equivalents $9.189M $11.02M $11.02M
Short-Term Investments
Other Short-Term Assets $39.00K $238.0K $238.0K
YoY Change -94.03% -19.05% -19.05%
Inventory
Prepaid Expenses $384.0K $34.00K
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $9.751M $11.26M $11.26M
YoY Change -14.26% -12.39% -12.39%
LONG-TERM ASSETS
Property, Plant & Equipment $87.00K $488.0K $488.0K
YoY Change -36.03% 251.08% 113.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $20.00K $20.00K $20.00K
YoY Change -59.18% -59.18% -59.18%
Total Long-Term Assets $488.0K $508.0K $508.0K
YoY Change 109.44% 82.73% 82.73%
TOTAL ASSETS
Total Short-Term Assets $9.751M $11.26M $11.26M
Total Long-Term Assets $488.0K $508.0K $508.0K
Total Assets $10.24M $11.77M $11.77M
YoY Change -11.78% -10.38% -10.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $66.00K $83.00K $83.00K
YoY Change -56.0% 388.24% 388.24%
Accrued Expenses $1.055M $1.008M $1.008M
YoY Change -21.5% -23.87% -23.87%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.121M $1.091M $1.091M
YoY Change -24.97% -18.64% -18.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $255.0K $288.0K $288.0K
YoY Change 696.88% 800.0% 800.0%
Total Long-Term Liabilities $255.0K $288.0K $288.0K
YoY Change 696.88% 800.0% 800.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.121M $1.091M $1.091M
Total Long-Term Liabilities $255.0K $288.0K $288.0K
Total Liabilities $1.376M $1.379M $1.379M
YoY Change -9.83% 0.44% 0.44%
SHAREHOLDERS EQUITY
Retained Earnings -$106.4M -$104.4M
YoY Change 8.92% 9.32%
Common Stock $115.2M $114.7M
YoY Change 6.96% 7.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.863M $10.39M $10.39M
YoY Change
Total Liabilities & Shareholders Equity $10.24M $11.77M $11.77M
YoY Change -11.78% -10.38% -10.38%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$2.017M -$1.995M -$8.889M
YoY Change -7.9% -34.27% -31.99%
Depreciation, Depletion And Amortization $13.00K $13.00K $56.00K
YoY Change -7.14% -18.75% -12.5%
Cash From Operating Activities -$1.862M -$2.617M -$7.310M
YoY Change 15.72% 30.13% -41.52%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $5.000K $17.00K
YoY Change -100.0% 66.67% -63.83%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 -$5.000K -$17.00K
YoY Change -100.0% 66.67% -83.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $6.616M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $30.00K 6.031M 6.036M
YoY Change 46330.77%
NET CHANGE
Cash From Operating Activities -$1.862M -2.617M -7.310M
Cash From Investing Activities $0.00 -5.000K -17.00K
Cash From Financing Activities $30.00K 6.031M 6.036M
Net Change In Cash -$1.832M 3.409M -1.291M
YoY Change 13.09% -269.27% -89.74%
FREE CASH FLOW
Cash From Operating Activities -$1.862M -$2.617M -$7.310M
Capital Expenditures $0.00 $5.000K $17.00K
Free Cash Flow -$1.862M -$2.622M -$7.327M
YoY Change 14.94% 30.19% -41.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11085000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12934000 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
32000 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11085000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12376000 usd
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2023 dei City Area Code
CityAreaCode
972
CY2023 dei Local Phone Number
LocalPhoneNumber
2-532-7151
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4510000 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8860000 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
137000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-8889000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-13071000 usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5000 usd
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
66000 usd
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
L3
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
Kiryat Hadassah
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Minrav Building - Fifth Floor
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
246000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
256000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28809922 shares
CY2023 us-gaap Revenues
Revenues
0 usd
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
101000 usd
CY2023 us-gaap Gross Profit
GrossProfit
0 usd
CY2022 us-gaap Gross Profit
GrossProfit
33000 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5848000 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4430000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
10386000 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-149000 usd
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-15000 usd
CY2023 entx Funds In Respect Of Employee Rights Upon Retirement
FundsInRespectOfEmployeeRightsUponRetirement
0 usd
CY2022 entx Funds In Respect Of Employee Rights Upon Retirement
FundsInRespectOfEmployeeRightsUponRetirement
55000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12376000 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0000769
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-38556
CY2023 dei Entity Registrant Name
EntityRegistrantName
Entera Bio Ltd.
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Jerusalem
CY2023 dei Entity Address Country
EntityAddressCountry
IL
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
9112002
CY2023 dei Trading Symbol
TradingSymbol
ENTX
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
20700000 usd
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35481341 shares
CY2023 dei Auditor Firm
AuditorFirmId
1309
CY2023 dei Auditor Name
AuditorName
Kesselman & Kesselman
CY2023 dei Auditor Location
AuditorLocation
Tel-Aviv, Israel
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
238000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
294000 usd
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28809922 shares
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104386000 usd
CY2022 us-gaap Revenues
Revenues
134000 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7253000 usd
CY2023 us-gaap Other Nonrecurring Income
OtherNonrecurringIncome
49000 usd
CY2022 us-gaap Other Nonrecurring Income
OtherNonrecurringIncome
51000 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
8891000 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
13050000 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-8891000 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-13017000 usd
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
31000 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
83000 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29000 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.45
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29007794 shares
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29007794 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28808090 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28808090 shares
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-13071000 usd
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2247000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-8889000 usd
CY2023 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
5000 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1689000 usd
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
29000 usd
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
66000 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6036000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24964000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
67000 usd
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
165000 usd
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5733087 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.3
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.63
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1798884 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.78
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2458863 shares
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
5511 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.14
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
34313 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.27
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
902009 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.3
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4208325 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.26
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3165677 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4208325 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1689000 usd
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2247000 usd
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
75800000 usd
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
67100000 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8860000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12934000 usd
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-37000 usd
CY2023 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
29000 usd
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1225000 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
855000 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19471000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
17645000 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
14000 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
43000 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
15025000 usd
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2620000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
17645000 usd
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1826000 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19471000 usd
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Security12b Title
Security12bTitle
Ordinary shares
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22565000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11754000 usd
CY2023 entx Issuance Of Ordinary Shares Warrants And Pre Funded Warrants Due To Private Placement Net Of Issuance Costs
IssuanceOfOrdinarySharesWarrantsAndPreFundedWarrantsDueToPrivatePlacementNetOfIssuanceCosts
5827000 usd
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
174000 usd
CY2023 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6611000 usd
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 usd
CY2023 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
580000 usd
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12376000 usd
CY2023 entx Interest Received
InterestReceived
18000 usd
CY2022 entx Interest Received
InterestReceived
0 usd
CY2023 entx Issuance Costs
IssuanceCosts
470000 usd
CY2022 entx Issuance Costs
IssuanceCosts
0 usd
CY2023 entx Right Of Use Assets Obtained In Exchange For New Operating Lease Liabilities
RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities
449000 usd
CY2022 entx Right Of Use Assets Obtained In Exchange For New Operating Lease Liabilities
RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities
0 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104400000 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<div> <div style="font-family:Times New Roman, Times, serif;font-weight:bold"> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"> <tr style="vertical-align:top"> <td style="text-align:right;vertical-align:top;width:36pt"> <div style="text-align:left;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>b.</span></span></span></span></span></div> </td> <td style="text-align:left;vertical-align:top;width:auto"> <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Use of estimates in the preparation of financial statements</span></span></span></span></span></div> </td> </tr> </table> </div> </div> <div style="margin-left:36pt;line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.</span></span></span></span></span></div> </div>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%"> <tr style="vertical-align:top"> <td style="text-align:right;vertical-align:top;width:36pt"> <div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span style="font-weight:bold">h.</span></span></span></span></span></span></div> </td> <td style="text-align:left;vertical-align:top;width:auto"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span style="font-weight:bold">Concentrations of credit risk</span></span></span></span></span></span></div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains cash held in checking accounts and deposits at financial institutions in major Israeli and U.S. banks. Management believes the Company is not exposed to significant credit risk to its current financial institution, but will continue to monitor regularly and adjust, if needed, to mitigate risk. The Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant.</span></span></span></span></span></div> </div>
CY2023 us-gaap Severance Costs1
SeveranceCosts1
128000 usd
CY2022 us-gaap Severance Costs1
SeveranceCosts1
132000 usd
CY2023 entx Severance Expenses
SeveranceExpenses
128000 usd
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7458542 shares
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6255235 shares
CY2023 us-gaap Payment For Contingent Consideration Liability Operating Activities
PaymentForContingentConsiderationLiabilityOperatingActivities
180000 usd
CY2023 entx Percentage Of Lessee Incremental Borrowing Rate
PercentageOfLesseeIncrementalBorrowingRate
0.1384
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
196000 usd
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
197000 usd
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
196000 usd
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
197000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
388000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
90000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
134000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
91000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
256000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
390000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
91000 usd
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.41
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
392244 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
4.97
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
135115 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
3.8
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7105414 shares
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y6M7D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.14
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.16
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
390000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
184000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
184000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
86000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
454000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
64000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
390000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4316859 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.29
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.57
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5733087 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.06
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7105414 shares
CY2022 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
174000 usd
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
29000 usd
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
174000 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29000 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
137000 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17427000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15428000 usd
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
983000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
877000 usd
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
220000 usd
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
158000 usd
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
19485000 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
17688000 usd
CY2023 ecd Trd Arr Ind Title
TrdArrIndTitle
officers or directors
CY2023 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001178913-24-000881-index-headers.html Edgar Link pending
0001178913-24-000881-index.html Edgar Link pending
0001178913-24-000881.txt Edgar Link pending
0001178913-24-000881-xbrl.zip Edgar Link pending
entx-20231231.xsd Edgar Link pending
ex1015101.jpg Edgar Link pending
ex1015102.jpg Edgar Link pending
ex1015103.jpg Edgar Link pending
ex1015104.jpg Edgar Link pending
ex1015105.jpg Edgar Link pending
ex1015106.jpg Edgar Link pending
ex1015107.jpg Edgar Link pending
exhibit_10-10.htm Edgar Link pending
exhibit_10-11.htm Edgar Link pending
exhibit_10-12.htm Edgar Link pending
exhibit_21-1.htm Edgar Link pending
exhibit_23-1.htm Edgar Link pending
exhibit_31-1.htm Edgar Link pending
exhibit_31-2.htm Edgar Link pending
exhibit_32-1.htm Edgar Link pending
exhibit_32-2.htm Edgar Link pending
exhibit_97.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image00011.jpg Edgar Link pending
image00012.jpg Edgar Link pending
image00013.jpg Edgar Link pending
image00014.jpg Edgar Link pending
image00015.jpg Edgar Link pending
image00016.jpg Edgar Link pending
image00017.jpg Edgar Link pending
image00018.jpg Edgar Link pending
image00019.jpg Edgar Link pending
image00020.jpg Edgar Link pending
image00021.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
entx-20231231_def.xml Edgar Link unprocessable
entx-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zk2431054.htm Edgar Link pending
zk2431054_htm.xml Edgar Link completed
entx-20231231_cal.xml Edgar Link unprocessable
entx-20231231_lab.xml Edgar Link unprocessable